Imugene to acquire exclusive licence for potentially transformational oncolytic virus technology - Proactive Investors Australia

Imugene to acquire exclusive licence for potentially transformational oncolytic virus technology  Proactive Investors AustraliaImugene Ltd (ASX:IMU) - A phase-one clinical trial in 30 patients with advanced tumours is expected to start in 2020 across a number of US cancer centres.